Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats

Journal of Inflammation

Hisham A Mosli³  Salah A Ghareib²  Osama M Ashour²  Essam A Abdel-Sattar⁴  Jaudah A Al-Maghrabi⁵  Shagufta T Mufti⁵  Ahmed A Elberry¹ 

[1]Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

[2]Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

[3]Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

[4]Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt

[5]Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

关键词: citral;    castration;    immunohistochemistry;    cytokines;    antiproliferative;    anti-inflammatory;    date palm pollen;    atypical prostatic hyperplasia;   

Others  :  824057
DOI  :  10.1186/1476-9255-8-40

 received in 2011-10-30, accepted in 2011-12-23,  发布年份 2011

【 摘 要 】

Background

Atypical prostatic hyperplasia (APH) is a pseudoneoplastic lesion that can mimic prostate adenocarcinoma because of its cytologic and architectural features. Suspension of date palm pollen (DPP) is an herbal mixture that is widely used in folk medicine for male infertility. The aim of the present study was to evaluate the effect of DPP suspension and extract on APH-induced rats.

Methods

APH was induced in adult castrated Wistar rats by both s.c. injection of testosterone (0.5 mg/rat/day) and smearing citral on shaved skin once every 3 days for 30 days. Saw palmetto (100mg/kg), DPP suspension (250, 500 and 1000 mg/kg), and lyophilized DPP extract (150,300 and 600 mg/kg) were given orally daily for 30 days. All medications were started 7 days after castration and along with testosterone and citral.

Results

The histopathological feature in APH-induced prostate rats showed evidence of hyperplasia and inflammation. Immunohistochemical examination revealed that the expressions of IL-6, IL-8, TNF-α, IGF-1 and clusterin were increased, while the expression of TGF-β1 was decreased that correlates with presence of inflammation. Moreover, histopathological examination revealed increased cellular proliferation and reduced apoptosis in ventral prostate. Both saw palmetto and DPP treatment has ameliorated these histopathological and immunohistochemical changes in APH-induced rats. These improvements were not associated with reduction in the prostatic weight that may be attributed to the persistence of edema.

Conclusion

DPP may have a potential protective effect in APH-induced Wistar rats through modulation of cytokine expression and/or upregulation of their autocrine/paracrine receptors.

【 授权许可】

   
2011 Elberry et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Kim J, Yanagihara Y, Kikugawa T, Ji M, Tanji N, Masayoshi Y, Freeman MR: A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology 2009, 150:3576-3583.
• [2]Helpap B: The biological significance of atypical hyperplasia of the prostate. Virchows Arch A Pathol Anat Histol 1980, 387:307-317.
• [3]Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, Di Silverio F: Prostate growth and inflammation. J Steroid Biochem Mol Biol 2008, 108:254-260.
• [4]Novara G, Galfano A, Berto RB, Ficarra V, Navarrete RV, Artibani W: Inflammation, apoptosis, and BPH: What is the evidence? Eur Urol Suppl 2006, 5:401-409.
• [5]Wang L, Yang J, Yang L, Liu Z: Chronic inflammation in benign prostatic hyperplasia: Implications for therapy. Medical Hypotheses 2008, 70:1021-1023.
• [6]Sandhu JS: Prostate cancer and chronic prostatitis. Current Urol Reports 2008, 9:328-332.
• [7]Fernandez F, de Beer PM, van der Merwe L, Heyns CF: COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis 2008, 29:2347-2350.
• [8]Rigas B, Sun Y: Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer 2008, 98:1157-1160.
• [9]Bahmanpour S, Talaei T, Vojdani Z, Panjehshahin MR, Poostpasand A, Zareei S, Ghaeminia M: Effect of Phoenix Dactylifera Pollen on Sperm Parameters and Reproductive system of Adult Male Rats. Iran J Med Sci 2006, 31:208-212.
• [10]Soliman FA, Soliman A: The gonad stimulating potency of date palm pollen grains. Experientia 1958, 14:92-93.
• [11]Bajpayee KK: Ethnobotany of Phoenix (Arecaceae). JETB 1997, 21:155-157.
• [12]Dostal LA, Faber CK, Zandee J: Sperm motion parameters in vas deferens and cauda epididymal rat sperm. Reprod Toxicol 1996, 10:231-235.
• [13]Ebeling L: Therapeutic results of defined pollen extract in patients with chronic prostatitis or BPH accompanied by chronic prostatitis. In Therapy of prostatitis. Edited by Schmiedt E, Alken JE, Bauer H W. Zuckschwerdt Verlag, MiInchen; 1986:154-160.
• [14]Buck AC, Rees RWM, Ebeling L: Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 1989, 64:496-499.
• [15]Golomb E, Kruglikova A, Dvir D, Parnes N, Abramovici A: Induction of Atypical Prostatic Hyperplasia in Rats by Sympathomimetic Stimulation. Prostate 1998, 34:214-221.
• [16]Sandford NL, Searle JW, Kerr JF: Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathol 1984, 16:406-410.
• [17]Engelstein D, Shmueli J, Bruhis S, Servadio C, Abramovici A: Citral and testosterone interaction in inducing benign and atypical prostatic hyperplasia in rats. Comp Biochem Physiol 1996, 115:169-177.
• [18]Scolnik MD, Servadio C, Abramovici A: Comparative Study of Experimentally Induced Benign and Atypical Hyperplasia in the Ventral Prostate of Different Rat Strains. J Androl 1994, 15:287-297.
• [19]Lillie RD: ''Histopathologic Techniques and Practical Histochemistry''. McGraw-Hill, New York; 1965.
• [20]De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011, 60:106-1017.
• [21]Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Bartsch G, Culig Z: Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000, 191:239-244.
• [22]Gounder SK, Chang VT, Hoover D, Gonzalez ML, Ahmed S, Finch-Cruz C, Duque L, Zhong F, Toomey K, Kasimis BS: Prostate cancer immunohistochemical (IHC) stains and survival in stage D3 patients (pts). J Clin Oncol 2008, 26:22187.
• [23]Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP: The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992, 70:291-301.
• [24]Abramovici A, Servadio C, Shmuely J, Sandbank U: Experimental induction of atypical hyperplasia in rat ventral prostate. In Prostate Cancer. Part A: Research. Endocrine Treatment and Histopathology. Edited by Murphy GP, Khoun S. Alan R Liss, New York; 1987:559-568.
• [25]Geldof AA, Enel C, Rao BR: Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia. Urol Res 1992, 20:139-144.
• [26]Brolin J, Skoog L, Ekman P: Immunohistochemistry and biochemistry in detection of androgen, progesterone and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992, 20:281-295.
• [27]Hoe S, Leav I, Merk FB, Yu M, Kwan PW, Ziar J: Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostate of noble rats treated with testosterone and pharmacologic doses of estradiol-17 β. Lab Invest 1995, 73:356-365.
• [28]Soulitzis N, Karyotis I, Delakas D, Spandidos DA: Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006, 29:305-314.
• [29]Marinese D, Patel R, Walden PD: Mechanistic Investigation of the Adrenergic Induction Of Ventral Prostate Hyperplasia in Mice. Prostate 2003, 54:230-237.
• [30]Wu S, Sun H, Qi X, Tu Z: Effect of Epristeride on the Expression of IGF-1 and TGF-beta Receptors in Androgen-Induced Castrated Rat Prostate. Exp Biol Med 2001, 226:954-960.
• [31]Furlanetto RW, Dicarlo JN, Wisehart C: The type II insulin-like growth factor receptor does not mediate deoxyribonucleic synthesis in human fibroblasts. J Clin Endocrinol Metab 1987, 64:1142-1149.
• [32]Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocke H: Regulation of prostatic growth and function by peptide growth factors. Prostate 1996, 28:392-405.
• [33]Kramer G, Marberger M: Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006, 16:25-29.
• [34]Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V: Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007, 52:964-972.
• [35]Giri D, Ozen M, Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Path 2001, 159:2159-2165.
• [36]Djavan B, Eckersberger E, Espinosa G, Kramer G, Handisurya A, Lee C, Marberger M, Lepor H, Steiner GE: Complex Mechanisms in Prostatic Inflammatory Response. Eur Urol Suppl 2009, 8:872-878.
• [37]Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, Vessella RL, Ralph D: Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999, 53:139-47.
• [38]Radeke HH, Meier B, Topley N, Floge J, Habermehl GG, Resch K: Interleukin 1a and tumor necrosis factor-a induce oxygen radical production in mesangial cells. J Clin Invest 1990, 37:767-775.
• [39]Descazeaud A, Weinbreck N, Robert G, Vacherot F, Abbou CC, Labrousse F, Allory Y, Rubin MA, de la Taille A: Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int 2011, 108(2Pt 2):E23-E28.
• [40]Ito R, Ishii A, Yamashita S: Cemitin pollenextract (Cernilton) Antiprostatic hypertrophic action of Cernitin pollen-extract (Cernilton). Pharmacometrics (Jpn.) 1986, 31:1-11.
• [41]Kimura M, Kimura I, Nakase K: Micturition activity of pollen extract: contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig. Planta Med 1986, 2:148-151.
• [42]Osborn DE, George NJR, Rao PN: Prostatodynia-physiological characteristics and rational management with muscle relaxants. Brit J Urol 1981, 53:621-623.
• [43]Nakase K, Takenaga K, Hamanaka T, Kimura M: Inhibitory effect and synergism of cernitin pollen extract on the urethral smooth muscle and diaphragm of the rat. Nippon Yakurigaku Zasshi 1988, 91:385-392.
• [44]Buck AC, Cox R, Rees RW, Ebeling L, John A: Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo controlled study. Br J Urol 1990, 66:398-404.
• [45]Vacher P, Prevarskaya N, Skryma R, Audy MC, Vacher AM, Odessa MF, Dufy B: The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 1995, 2:357-365.
• [46]Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A, Petrangeli E: Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 1996, 29:219-230.
• [47]Bayne CW, Grant ES, Chapman K: Characterization of a new coculture model for BPH which expresses 5-alpha-reductase types I and II: the effects of Permixon on DHT formation (abstract 70). Fourth International Consultation on BPH, Paris; 1997:70.